22(R)-hydroxycholesterol and pioglitazone synergistically decrease cholesterol ester via the PPAR纬-LXR伪-ABCA1 pathway in cholesterosis of the gallbladder
详细信息 查看全文
- 作者：Jing-Min Wang wjm730222@163.com" class="auth_mail ; Dong Wang 8888dd@163.com" class="auth_mail ; Yu-Yan Tan tyytyz@sina.com" class="auth_mail ; Gang Zhao zhao_gang7@126.com" class="auth_mail ; Zhen-Ling Ji ; zlji@me.com" class="auth_mail
- 关键词：Cholesterosis ; 22(R)-hydroxycholesterol ; Pioglitazone ; ABCA1 ; PPAR纬 ; LXR伪
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：25 April 2014
- 年：2014
- 卷：447
- 期：1
- 页码：152-157
- 全文大小：1497 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Cholesterosis is a metabolic disease characterized by excessive lipid droplets.
- class="label">•
Lipid droplet efflux is mediated by the ABCA1 transporter.
- class="label">•
22(R)-hydroxycholesterol can activate LXR伪 and up-regulate ABCA1.
- class="label">•
Pioglitazone up-regulates ABCA1 in a PPAR纬–LXR伪–ABCA1-dependent manner.
- class="label">•
22(R)-hydroxycholesterol and pioglitazone synergistically decrease lipid droplets.